Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study

Khandekar, Melin J.; Jain, Rakesh K.

doi:10.21037/tcr.2017.12.17

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent years, immunotherapy hits the spotlight with its remarkable breakthrough in cancer treatment (5)(6)(7). Unfortunately, the mechanism of tumor immunotherapy is not fully understood.…”

Section: Introductionmentioning

confidence: 99%

T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer

Jia¹,

He²,

Dziadziuszko³

et al. 2019

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: Immunotherapy has shown promising effect for non-small cell lung cancer (NSCLC) patients. Yet the biomarkers for predicting immunotherapy efficiency are still lacking. Methods: We tested 139 surgical resected NSCLC primary tumor samples from Medical University of Gdansk, Poland, for T cell immunoglobulin and mucin-domain containing-3 (TIM-3) level by immunohistochemistry (IHC), analyzed the expression of TIM-3 protein on NSCLC tumor cells and tumor infiltrating lymphocytes (TILs). Results: TIM-3 on TILs was correlated with programmed cell death protein-1 (PD-1) on TILs (correlation coefficient =0.346, P<0.001) and programmed cell death protein-ligand 1 (PD-L1) on TILs (correlation coefficient =0.313, P<0.001), PD-L1 level on tumor cells (correlation coefficient =0.255, P=0.002), TIM-3 level on tumor cells (correlation coefficient =0.262, P=0.002) and TIL percentage (correlation coefficient =0.172, P=0.043). TIM-3 level on tumor cells only had correlation with PD-L1 level (correlation coefficient =0.170, P=0.045). High level of TIM-3 on TILs indicated shorter recurrence-free survival (RFS) and overall

show abstract

“…Recent years, immunotherapy hits the spotlight with its remarkable breakthrough in cancer treatment (5)(6)(7). Unfortunately, the mechanism of tumor immunotherapy is not fully understood.…”

Section: Introductionmentioning

confidence: 99%

T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer

Jia¹,

He²,

Dziadziuszko³

et al. 2019

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

“…Anti-PD-1/PD-L1 agents could lead to dermatologic toxicity (1). It has been reported that skin toxicity may occur in more than 40% melanoma patients treated with anti-PD-1 monoclonal antibodies (mAbs) (2). A meta-analysis showed that the average incidence of dermatotoxicity is 44% in patients receiving anti-CTLA-4 therapy (3).…”

Section: Dermatologic Toxicitiesmentioning

confidence: 99%

Toxicity of tumor immune checkpoint inhibitors—more attention should be paid

Liu

Wang

Deng

et al. 2019

Transl Lung Cancer Res

View full text Add to dashboard Cite

In recent years, immunotherapy, especially immune checkpoint inhibitors (ICIs), has achieved amazing results in the treatment of lung cancer, melanoma, renal clear cell carcinoma and other malignant tumors. Although ICIs have achieved significant efficacy in tumor treatment, the immune-related adverse events (irAEs) caused by non-specific immune activation of ICIs can directly affect the result of treatment, even threaten the life of patients. The most common form of irAEs involve the skin, lung, colon, liver and endocrine organs. However, it is noticeable that although irAEs of some organs are more common, actually any organ and tissue are likely to be affected, because of non-specific activation of the immune system.Other tissues and organs, though rare, can be more severe and even fatal, such as neurological disorders and myocarditis. Therefore, effective management of irAEs is of great importance for the efficacy of immunotherapy. This review is focused on the morbidity, clinical manifestations, diagnosis and treatment of tumor immune toxic effects.

show abstract

“…Yet, the 4.9% incidence of mediastinal recurrence was lower than that would be expected historically, raising the hypothesis of distant immune effects with the use of SBRT. Indeed, the possibility of tumor antigen presentation with ablative treatments and its impact on immunotherapeutic treatments is yet to be fully explored, and there are ongoing clinical trials combining SBRT with immunotherapy in lung cancer …”

Section: Opening Statementsmentioning

confidence: 99%

Three discipline collaborative radiation therapy (3DCRT) special debate: I would treat all early‐stage NSCLC patients with SBRT

Mohindra

Sawant

Griffin

et al. 2019

J Applied Clin Med Phys

View full text Add to dashboard Cite

Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study

Cited by 4 publications

References 26 publications

T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer

T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer

Toxicity of tumor immune checkpoint inhibitors—more attention should be paid

Three discipline collaborative radiation therapy (3DCRT) special debate: I would treat all early‐stage NSCLC patients with SBRT

Contact Info

Product

Resources

About